Therapeutic Manufacturing

The Therapeutic Manufacturing resource supports the development and manufacturing of novel biological molecules and innovative cell-based therapies for Phase I/II clinical testing.   This resource allows the Consortium to build on it’s leadership role in the application of immunotherapy for the treatment of hematological malignancies, and to extend this innovative work to other clinical settings such as autoimmune disorders, melanoma, breast, ovary, and prostate cancer.  These facilities permit the reproducible production of large-scale quantities of biological reagents and therapeutic cells under the strict quality control and safety conditions required by the FDA for human studies.  Successful development of such materials will have obvious significance for many patients.  Further, progress in pursuit of these aims will have relevance for other clinical situations, teaching us valuable lessons about the molecular basis for disease progression, induction of transplant tolerance, response to infectious diseases, and especially about immunotherapy approaches for the treatment of cancer.

Locations: 
Fred Hutchinson Cancer Research Center
University of Washington Medical Center

Director of Manufacturing: 
Ron Manger, PhD

Quality Assurance Director: 
Catherine Lindgren

Scientific Advisor: 
Shelly Heimfeld, PhD

Medical Director: 
Michael Linenberger, MD

For additional information:
http://www.fhcrc.org/science/shared_resources/therapeutic_manufacturing/